Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kirk Sigurd Insider Profile
4 Followers
Kirk Sigurd, Director at Aravive, holds ― shares in Aravive (Ticker: ARAV), holds 53.75K shares in Assertio Therapeutics (Ticker: ASRT). Most recently, Kirk Sigurd ― shares of Aravive on ― for an estimated value of ―.
Kirk Sigurd Aravive (ARAV)Director
Aravive (ARAV)
Director
Not Ranked
Kirk Sigurd has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Kirk Sigurd holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kirk Sigurd
Kirk Sigurd's Trading History
Aravive
―
―
―
―
Assertio Therapeutics
May 28, 2024
Director
Uninformative Buy
―
$69.88K
List of latest transactions for each holding click on a transaction to see Kirk Sigurd's performance on stock
You May Also Like
Kirk Sigurd insider profile FAQ
What is the percentage of profitable transactions made by Kirk Sigurd?
The percentage of profitable transactions made by Kirk Sigurd is ―.
What is the average return per transaction made by Kirk Sigurd?
The average return per transaction made by Kirk Sigurd is ―.
What stocks does Kirk Sigurd hold?
Kirk Sigurd holds: ARAV, ASRT stocks.
What was Kirk Sigurd’s latest transaction?
Kirk Sigurd latest transaction was an Uninformative Buy of ―.
What was Kirk Sigurd's most profitable transaction?
Kirk Sigurd’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kirk Sigurd's role in Aravive?
Kirk Sigurd's role in Aravive is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.